Associate Director, Hematology, Strategic Forecasting & Portfolio Analytics
CSL
About this role
The Associate Director, Strategic Forecasting and Portfolio Analytics leads forecasting programs for CSL’s portfolio, serving as the primary forecasting contact for commercial development of in-line and pipeline hematology assets. The role drives long-range planning, influences R&D and clinical strategy, and partners across commercial, R&D, and finance to inform go/no-go decisions. The position also manages contractors and offshore resources to deliver global volume and revenue forecasts.
Skills
Qualifications
About CSL
csl.comCSL is a leading global biotechnology company dedicated to creating lifesaving medicines. With a portfolio that includes therapies for rare diseases, immune deficiencies, and vaccines for influenza, CSL's mission is rooted in innovation and public health. The organization comprises three distinct businesses: CSL Behring, focused on plasma-derived therapies; CSL Seqirus, specializing in influenza vaccines; and CSL Vifor, addressing iron deficiency and nephrology. Since its founding in 1916, CSL has been committed to ensuring access to essential treatments for patients in over 100 countries.
Recent company news
About CSL
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for CSL.
Salary
$195k – $259k
per year
More jobs at CSL
Similar Jobs
Director, Global Pipeline Forecasting & Analytics—Oncology
AbbVie
Manager - Forecasting
Diversity Employment
Sr. Director, Commercial Forecasting & Analytics
Neurocrine Biosciences
Director, Forecasting and Analytics, North America
BeOne Medicines
CD&A - Senior Manager, US Forecasting
Amgen
Head of Early Assets, Hematology
AstraZeneca